Intec Pharma Company Profile (NASDAQ:NTEC)

About Intec Pharma (NASDAQ:NTEC)

Intec Pharma logoIntec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson's disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NTEC
  • CUSIP: N/A
  • Web:
  • Market Cap: $102.46 million
  • Outstanding Shares: 13,738,000
Average Prices:
  • 50 Day Moving Avg: $7.75
  • 200 Day Moving Avg: $7.75
  • 52 Week Range: $4.20 - $9.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.22
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.57 per share
  • Price / Book: 5.70
  • EBIDTA: ($17,650,000.00)
  • Current Ratio: 6.40%
  • Quick Ratio: 6.40%
  • Average Volume: 82,643 shs.
  • Beta: 1.31
  • Short Ratio: 0.87

Frequently Asked Questions for Intec Pharma (NASDAQ:NTEC)

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd. (NASDAQ:NTEC) posted its quarterly earnings data on Thursday, November, 5th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.09. View Intec Pharma's Earnings History.

When will Intec Pharma make its next earnings announcement?

Intec Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Intec Pharma.

Where is Intec Pharma's stock going? Where will Intec Pharma's stock price be in 2017?

4 brokerages have issued twelve-month price targets for Intec Pharma's stock. Their predictions range from $9.00 to $15.00. On average, they expect Intec Pharma's stock price to reach $12.25 in the next year. View Analyst Ratings for Intec Pharma.

What are analysts saying about Intec Pharma stock?

Here are some recent quotes from research analysts about Intec Pharma stock:

  • 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (9/22/2017)
  • 2. Maxim Group analysts commented, " As Intec initiates phase I trials of CBD/THC using the accordion delivery system, it opens up a new option for shareholders. The company extends the potential therapeutic utility of its proprietary delivery system beyond Parkinson's disease and insomnia. Cannabinoid-based therapeutics is a large, growing market, and as such, we look forward to any positive progress in this program which could be another value driver for the company." (3/24/2017)

Who are some of Intec Pharma's key competitors?

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the folowing people:

  • John W. Kozarich, Chairman of the Board
  • Jeffrey A. Meckler, Chief Executive Officer, Vice Chairman of the Board
  • Nir Sassi, Chief Financial Officer
  • Nadav Navon, Chief Operating Officer
  • Liat Flaishon, Vice President-Clinical and Business Development
  • Giora Carni, Director

When did Intec Pharma IPO?

(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.

Who owns Intec Pharma stock?

Intec Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Migdal Insurance & Financial Holdings Ltd. (3.80%). View Institutional Ownership Trends for Intec Pharma.

Who bought Intec Pharma stock? Who is buying Intec Pharma stock?

Intec Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Migdal Insurance & Financial Holdings Ltd.. View Insider Buying and Selling for Intec Pharma.

How do I buy Intec Pharma stock?

Shares of Intec Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intec Pharma's stock price today?

One share of Intec Pharma stock can currently be purchased for approximately $8.95.

MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)
Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  139
MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intec Pharma (NASDAQ:NTEC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.25 (36.87% upside)

Analysts' Ratings History for Intec Pharma (NASDAQ:NTEC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017CIBCReiterated RatingOutperform -> Outperform$10.00 -> $15.00MediumView Rating Details
9/21/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$10.00 -> $15.00HighView Rating Details
8/10/2017Roth CapitalSet Price TargetBuy$10.00HighView Rating Details
5/24/2017Maxim GroupSet Price TargetBuy$9.00LowView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for Intec Pharma (NASDAQ:NTEC)
Earnings by Quarter for Intec Pharma (NASDAQ:NTEC)
Earnings History by Quarter for Intec Pharma (NASDAQ NTEC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/5/2015Q3 2015($0.07)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intec Pharma (NASDAQ:NTEC)
2017 EPS Consensus Estimate: ($1.28)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.31)($0.31)($0.31)
Q2 20171($0.31)($0.31)($0.31)
Q3 20172($0.34)($0.31)($0.33)
Q4 20172($0.36)($0.31)($0.34)
(Data provided by Zacks Investment Research)


Dividend History for Intec Pharma (NASDAQ:NTEC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Intec Pharma (NASDAQ:NTEC)
No insider trades for this company have been tracked by


Headline Trends for Intec Pharma (NASDAQ:NTEC)
Latest Headlines for Intec Pharma (NASDAQ:NTEC)
DateHeadline logoIntec Pharma Ltd. (NTEC) Raised to Hold at Zacks Investment Research - September 23 at 10:10 AM logoIntec Pharma to Participate in the Ladenburg Thalmann 2017 Healthcare Conference - September 22 at 11:40 AM logoIntec Pharma Ltd. (NTEC) Receives Consensus Recommendation of "Hold" from Analysts - September 21 at 10:40 AM logoIntec Pharma Ltd. (NTEC) Receives "Outperform" Rating from CIBC - September 21 at 10:22 AM logoIntec Pharma Ltd. (NTEC) Price Target Raised to $15.00 at Oppenheimer Holdings, Inc. - September 21 at 10:02 AM logoTherapix Biosciences: Another Favorite Marijuana Play - September 17 at 6:01 AM logoBRIEF-Acuta Capital Partners reports 10.5 pct passive stake in Intec Pharma - September 10 at 4:07 AM logoIntec Pharma to Participate in the 19th Annual Rodman & Renshaw Global Investment Conference - September 9 at 6:47 AM logoIntec Pharma to Participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference - September 2 at 6:56 AM logoIntec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in Session - August 23 at 9:19 AM logoIntec Pharma Announces Closing of $57.5 Million Public Offering of Ordinary Shares - August 22 at 12:18 AM logoPull The Trigger On Intec Pharma's Offering - August 19 at 6:05 AM logoIntec Pharma (NTEC) Prices 10.6M Share Offering at $4.70/Sh - August 17 at 6:20 AM logoIntec Pharma Announces Pricing of $50.0 Million Public Offering of Ordinary Shares - August 17 at 6:20 AM logoIntec Pharma (NTEC) Plans Public Offering of Ordinary Shares - August 16 at 2:33 AM logoBRIEF-Intec Pharma announces proposed public offering of ordinary shares - August 15 at 4:28 PM logoIntec Pharma Announces Proposed Public Offering of Ordinary Shares - August 15 at 4:28 PM logoBRIEF-Intec Pharma reports financial results for the first half of 2017 - August 10 at 6:20 AM logoIntec Pharma Reports Financial Results for the First Six Months of 2017 - August 10 at 6:20 AM logoIntec Pharma Ltd (NTEC) Given a $10.00 Price Target at Roth Capital - August 6 at 6:28 PM logoBRIEF-Intec Pharma reports clinical results from phase I trial of accordion pill for cannabinoid therapies - August 4 at 3:48 PM logoIntec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill for Cannabinoid Therapies - August 4 at 6:29 AM logoIntec Pharma Promotes Nadav Navon, Ph.D. to Chief Operating Officer - July 28 at 6:14 AM logoIntec Pharma Granted Patent in Hong Kong for Accordion Pill™ Carbidopa / Levodopa - July 20 at 2:44 AM logoIntec Pharma Appoints U.S. Life Sciences Executive and Vice Chairman Jeffrey A. Meckler as Chief Executive Officer - July 11 at 5:53 AM logoZacks: Brokerages Expect Intec Pharma Ltd. (NASDAQ:NTEC) to Announce -$0.31 EPS - July 4 at 8:51 AM logoValuEngine Downgrades Intec Pharma Ltd (NTEC) to Sell - June 9 at 3:22 PM logoZacks: Analysts Anticipate Intec Pharma Ltd (NTEC) Will Announce Earnings of -$0.31 Per Share - June 8 at 7:40 AM logoIntec Pharma to Participate at Upcoming June Conferences - May 31 at 10:52 AM logoZacks Investment Research Downgrades Intec Pharma Ltd (NTEC) to Hold - May 27 at 9:28 PM logoIntec Pharma Ltd (NTEC) PT Set at $9.00 by Maxim Group - May 25 at 4:56 PM logoIntec Pharma (NTEC) Granted U.S. Patent for Accordion Pill - May 24 at 7:06 PM logoIntec Pharma Granted U.S. Patent for Accordion Pill™ Comprising Levodopa for Improved Treatment of Parkinson's Diseases Symptoms - May 24 at 10:24 AM logoIntec Pharma Ltd (NTEC) Expected to Announce Earnings of -$0.31 Per Share - May 12 at 7:40 AM logoIntec Pharma (NTEC) Given Media Impact Rating of 0.12 - May 5 at 10:34 PM logoIntec Pharma Announces CEO Change - May 3 at 8:03 PM logoIntec Pharma (NTEC) Given Coverage Optimism Rating of 0.26 - April 28 at 12:26 AM logoBRIEF-Intech Biopharm signs agreement with TWi Pharmaceuticals on joint development of asthma drugs - April 26 at 6:20 PM logoIntec Pharma (NTEC) Getting Favorable Media Coverage, Report Finds - April 24 at 3:20 PM logoIntec Pharma (NTEC) Earns Daily Media Sentiment Score of 0.50 - April 17 at 12:56 PM logoIntec Pharma (NTEC) Earning Positive News Coverage, Analysis Shows - April 13 at 7:46 PM logoIntec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman - April 9 at 9:41 AM logoIntec Pharma Ltd (NTEC) Short Interest Up 1,208.7% in March - April 7 at 8:00 PM logoBRIEF-Intec Pharma files for resale of 2.1 mln ordinary shares - April 7 at 11:33 AM logoIntec Pharma Reports 2016 Fourth Quarter and Full Year Financial Results - April 7 at 11:33 AM logo Intec Pharma Ltd (NTEC) Given Consensus Rating of "Strong Buy" by Analysts - April 6 at 8:04 AM logoBRIEF-Intec Pharma provides update on phase III accordance study of the accordion pill - March 29 at 9:24 AM logoIntec Pharma Provides Update on Phase III ACCORDANCE Study of the Accordion Pill Carbidopa/Levodopa in Parkinson's Disease Patients - March 29 at 9:24 AM logoIntec Pharma Ltd (NTEC) Raised to Buy at Zacks Investment Research - March 24 at 3:02 PM logoIntec Pharma Ltd (NTEC) Rating Reiterated by Maxim Group - March 24 at 11:13 AM



Intec Pharma (NTEC) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff